Trexquant Investment LP Raises Stock Holdings in Personalis, Inc. $PSNL

Trexquant Investment LP raised its position in shares of Personalis, Inc. (NASDAQ:PSNL - Free Report) by 455.0% in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 122,959 shares of the company's stock after buying an additional 100,804 shares during the period. Trexquant Investment LP owned about 0.14% of Personalis worth $432,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Point72 Asia Singapore Pte. Ltd. purchased a new stake in Personalis in the 4th quarter valued at approximately $28,000. Alpine Global Management LLC acquired a new stake in shares of Personalis in the fourth quarter valued at approximately $60,000. Raymond James Financial Inc. acquired a new position in shares of Personalis during the fourth quarter valued at approximately $64,000. Schonfeld Strategic Advisors LLC bought a new stake in Personalis during the fourth quarter worth approximately $83,000. Finally, China Universal Asset Management Co. Ltd. boosted its stake in shares of Personalis by 18.2% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 17,704 shares of the company's stock valued at $62,000 after buying an additional 2,724 shares during the period. 61.91% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on PSNL. Wall Street Zen downgraded shares of Personalis from a "hold" rating to a "sell" rating in a report on Saturday, August 9th. HC Wainwright reiterated a "buy" rating and issued a $8.50 price target on shares of Personalis in a report on Monday, September 8th. Finally, BTIG Research set a $6.00 target price on shares of Personalis in a report on Wednesday, August 6th. Five equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the company has an average rating of "Buy" and a consensus price target of $7.42.

Personalis Stock Down 4.1%

Shares of NASDAQ:PSNL traded down $0.25 on Friday, hitting $5.85. 1,006,825 shares of the company traded hands, compared to its average volume of 830,451. Personalis, Inc. has a 52 week low of $2.83 and a 52 week high of $7.79. The stock has a 50 day simple moving average of $5.50 and a 200-day simple moving average of $4.86. The company has a market cap of $518.76 million, a PE ratio of -4.57 and a beta of 1.76.

Personalis (NASDAQ:PSNL - Get Free Report) last posted its quarterly earnings data on Tuesday, August 5th. The company reported ($0.23) earnings per share for the quarter, beating analysts' consensus estimates of ($0.25) by $0.02. Personalis had a negative return on equity of 47.57% and a negative net margin of 113.70%.The firm had revenue of $17.20 million for the quarter, compared to analysts' expectations of $20.12 million. Personalis has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. As a group, sell-side analysts anticipate that Personalis, Inc. will post -1.4 earnings per share for the current year.

About Personalis

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.